The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.
Yongjun Cha
No relevant relationships to disclose
Yu Jung Kim
No relevant relationships to disclose
Tae Min Kim
No relevant relationships to disclose
Seung Hong Choi
No relevant relationships to disclose
Se-Hoon Lee
No relevant relationships to disclose
Dong-Wan Kim
No relevant relationships to disclose
Chul-Kee Park
No relevant relationships to disclose
Il Han Kim
No relevant relationships to disclose
Jee Hyun Kim
No relevant relationships to disclose
Eunhee Kim
No relevant relationships to disclose
Byung Se Choi
No relevant relationships to disclose
Chae-yong Kim
No relevant relationships to disclose
In Ah Kim
No relevant relationships to disclose
Dae Seog Heo
No relevant relationships to disclose